A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Muscular dystrophies
  • Focus Adverse reactions; First in man
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 08 Jul 2016 According to an Acceleron Pharma media release, results from this trial were presented at the 14th International Congress on Neuromuscular Disease.
    • 08 Jul 2016 Results published in the Acceleron Pharma media release.
    • 29 Jun 2016 According to an Acceleron Pharma media release, results from this trial will be presented at the 14th International Congress on Neuromuscular Disease (ICNMD 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top